This paper is only available as a PDF. To read, Please Download here.
Abstract
Background: The antihyperglycemic effects of pioglitazone hydrochloride and rosiglitazone maleate
are well documented. The results of clinical trials and observational studies have
suggested, however, that there are individual differences in the effects of these
drugs on blood lipid levels.
Objective: The present study evaluated the effects of pioglitazone and rosiglitazone on blood
lipid levels and glycemic control in patients with type 2 diabetes mellitus.
Methods: This was a retrospective review of randomly selected medical records from 605 primary
care practices in the United States in which adults with type 2 diabetes received
pioglitazone or rosiglitazone between August 1, 1999, and August 31, 2000. The outcome
measures were mean changes in serum concentrations of triglycerides (TG), total cholesterol
(TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol
(LDL-C), and glycosylated hemoglobin (HbA1c) values.
Results: Treatment with pioglitazone was associated with a reduction in mean TG of 55.17 mg/dL,
a reduction in TC of 8.45 mg/dL, an increase in HDL-C of 2.65 mg/dL, and a reduction
in LDL-C of 5.05 mg/dL. Treatment with rosiglitazone was associated with a reduction
in mean TG of 13.34 mg/dL, an increase in TC of 4.81 mg/dL, a reduction in HDL-C of
0.12 mg/dL, and an increase in LDL-C of 3.56 mg/dL. With the exception of HDL-C, the
differences in mean changes in lipid parameters between treatment groups were statistically
significantly (P < 0.001, pioglitazone vs rosiglitazone). Reductions in HbA1c were statistically equivalent between treatments (1.04% pioglitazone, 1.18% rosiglitazone).
Conclusions: Treatment with pioglitazone was associated with greater beneficial effects on blood
lipid levels than treatment with rosiglitazone, whereas glycemic control was equivalent
between the 2 treatments.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Nonhypoglycemic effects of thiazolidinediones.Ann Intern Med. 2001; 134: 61-71
- Thiazolidine-diones: An update.Lancet. 2000; 355: 1008-1010
- Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.J Clin Invest. 2000; 106: 467-472
- Medical significance of peroxisome proliferator-activated receptors.Lancet. 1999; 354: 141-148
- Hepatic dysfunction associated with troglitazone.N Engl J Med. 1998; 338 (Letter): 916-917
- An autopsy case of troglitazone-induced fulminant hepatitis.Diabetes Care. 1998; 21: 2140-2143
- Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone.Ann Intern Med. 1998; 129: 36-38
- Actos™ (pioglitazone hydrochloride) tablets. Takeda Pharmaceuticals America, Inc, Lincolnshire, Ill1999 ([package insert])
- Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4.Br Med J. 2001; 322 (Letter): 235-236
- Hepatocellular injury in a patient receiving pioglitazone.Ann Intern Med. 2001; 135 (Letter): 306
- Avandia® (rosiglitazone maleate) tablets. GlaxoSmithKline, Research Triangle Park, NC2001 ([package insert])
- Hepatocellular injury in a patient receiving rosiglitazone. A case report.Ann Intern Med. 2000; 132: 121-124
- Hepatic failure in a patient taking rosiglitazone.Ann Intern Med. 2000; 132: 118-121
- Rosiglitazone and hepatic failure.Ann Intern Med. 2000; 132 (Letter): 164
- Rosiglitazone and liver failure.Ann Intern Med. 2000; 133 (Letter): 393-394
- Rosiglitazone toxicity.Ann Intern Med. 2000; 133 (Letter): 658
- The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.Coron Artery Dis. 2001; 12: 413-423
- Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study.Am J Med. 2001; 111: 10-17
- Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study.Diabetes Care. 2000; 23: 1605-1611
- Rosiglitazone monotherapy is effective in patients with type 2 diabetes.J Clin Endocrinol Metab. 2001; 86: 280-288
- Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: A twelve-week, randomized, placebo-controlled study.Diabetes Obes Metab. 1999; 1: 165-172
- Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.Diabetes Care. 2001; 24: 308-315
- Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial.JAMA. 2000; 283: 1695-1702
- Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus.Diabet Med. 2000; 17: 287-294
- Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.Diabetologia. 2000; 43: 278-284
- Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients.Diabet Med. 2000; 17: 40-47
- A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.Diabetes Care. 2001; 24: 1226-1232
- Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study.Clin Ther. 2000; 22: 1395-1409
- Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.Diabetes Care. 2001; 24: 710-719
- Comparison of the glucose and lipid effects of rosiglitazone (ROS) and pioglitazone (PIO) following conversion from troglitazone (TRO) treatment.Diabetes. 2001; 50 (Abstract): A120-A121
- A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.Diabetes Care. 2000; 23 (Letter): 557
- A prospective, randomized comparison of the metabolic effects of pioglitazone vs rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.Diabetes. 2001; 50 (Abstract): A119
- Comparison of effects of thiazolidinediones on cardiovascular risk factors: Observations from a clinical practice.Endocr Pract. 2001; 7: 162-169
- 3rd ed. Biostatistical Analysis. Prentice Hall, Upper Saddle River, NJ1996
- Prediction of coronary heart disease using risk factor categories.Circulation. 1998; 97: 1837-1847
- National Diabetes Fact Sheet: National Estimates and General Information on Diabetes in the United States. US Dept of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Ga1998 (Revised)
The impact of diabetes. American Diabetes Association Web site. Available at: http://www.diabetes.org/main/application/commercewf?origin=*.jsp&event=link(B1_1). Accessed July 27, 2001.
- Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23).Br Med J. 1998; 316: 823-828
- Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).JAMA. 2001; 285: 2486-2497
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study.Br Med J. 2000; 321: 405-412
- Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study.Circulation. 1998; 97: 1029-1036
- Hypertriglyceridemia as a cardiovascular risk factor.Am J Cardiol. 1998; 81: 7B-12B
- Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.N Engl J Med. 1999; 341: 410-418
- The emergence of triglycerides as a significant independent risk factor in coronary artery disease.Eur Heart J. 1998; 19 (Suppl M): M8-M14
- In vivo stimulation of vascular plasminogen activator inhibitor-1 production by very low-density lipoprotein involves transcription factor binding to a VLDL-responsive element.Thromb Haemost. 2000; 84: 706-711
- Heart disease in diabetes mellitus.Endocrinol Metab Clin North Am. 1996; 25: 425-438
- Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia.Arterioscler T Thromb Vasc Biol. 1998; 18: 20-26
- VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: Involvement of the VLDL receptor.J Lipid Res. 1999; 40: 913-919
- Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: A potential factor predisposing to thrombosis and its persistence.Circulation. 1998; 97: 2213-2221
- Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.Biochem Biophys Res Commun. 1999; 258: 431-435
- Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).Circulation. 1994; 89: 1333-1445
- Randomized, controlled trials, observational studies, and the hierarchy of research designs.N Engl J Med. 2000; 342: 1887-1892
- A comparison of observational studies and randomized, controlled trials.N Engl J Med. 2000; 342: 1878-1886
Article info
Publication history
Accepted:
January 7,
2002
Identification
Copyright
© 2002 Published by Elsevier Inc.
